UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  ______________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934.

Date of Report:  February 21, 2014

(Date of earliest event reported)

MRI Interventions, Inc.

(Exact name of registrant as specified in its charter)

(901) 522-9300

(Registrant's telephone number, including area code)

Not Applicable

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01. Entry into a Material Definitive Agreement.

On February 21, 2014, MRI Interventions, Inc. (the “Company”) and Siemens Medical Solutions USA, Inc. (“Siemens Medical”), entered into a Development Agreement (the “Development Agreement”). This new Development Agreement replaces and supersedes the original Cooperation and Development Agreement entered into between the Company and Siemens Aktiengesellschaft, Healthcare Sector (“Siemens AG”) in May 2009 (the “Original Agreement”). Therefore, upon execution of the new Development Agreement, on February 21, 2014, the Company and Siemens AG terminated the Original Agreement. References below to “Siemens” will mean Siemens Medical or Siemens AG, as applicable.

Under the Original Agreement, Siemens and the Company performed initial work related to the development of hardware and software needed for MRI-guided, catheter-based ablation procedures to treat cardiac arrhythmias, such as atrial fibrillation. Pursuant to the terms of the Original Agreement, the Company generally was responsible for developing catheters and other hardware, and Siemens was responsible for developing software, to the Company’s specifications. The Company was responsible for paying Siemens for its software development work, but, under the Original Agreement, Siemens owned the software. Working closely with the Company, Siemens created a research version of the software platform specifically for use in MRI-guided cardiac ablation procedures with the Company’s catheters, but a commercial version was not developed under the Original Agreement.

Under the new Development Agreement, Siemens and the Company are furthering their collaboration. The Company, with cooperation, assistance and technical support from Siemens, will develop the commercial version of the research software platform created by Siemens under the Original Agreement. Once the development work is completed, subject to appropriate regulatory clearance or approval, the Company will sell the software as its own product. The software will serve as the software component of the Company’s ClearTrace system. The full ClearTrace system, which is in development, is an integrated system of software, reusable hardware and disposable catheters designed to enable catheter-based procedures to be performed under MRI guidance instead of fluoroscopic guidance. Both Siemens and the Company believe a shift to MRI-guidance is significant because MRI provides superior visualization of soft tissue, MRI provides continuous 3-D visualization, and MRI eliminates all radiation exposure for the patient and physician.

Pursuant to the Development Agreement, Siemens will develop certain software features for a planned software release (the “Host Features”) for certain Siemens MAGNETOM MRI systems (“MAGNETOM Systems”). The Host Features will enable the connection of the Company’s software and catheters to MAGNETOM Systems, and the Company will pay Siemens to perform development work for the Host Features. The Host Features, which will be owned by Siemens, will run within the MRI scanner system. The Host Features will then connect to the Company’s software, which will operate on a separate computer workstation, and enable the performance of MRI-guided cardiac ablation procedures. Siemens expects to commercially release the Host Features in Europe first, followed by release in the United States. Once the Host Features are commercially released, Siemens will thereafter maintain the Host Features for the MAGNETOM Systems. In addition, for the term of the Development Agreement, Siemens will maintain technical compatibility of the Host Features with the Company’s software.

The Development Agreement provides for certain commercial exclusivity, generally extending for a period of four years following the European product release date of the Host Features, in the field of MRI-guided catheter-based cardiac electrophysiology using catheters that are actively tracked by the MRI scanner. During that period and within that field, the parties intend for the Company to have the exclusive opportunity to commercialize MRI-guided catheter-based cardiac electrophysiology with active catheter tracking with Siemens MRI systems, and accordingly, Siemens agreed that it will not engage in certain actions and activities. Likewise, during that period and within that field, the Company agreed that it will not sell or otherwise provide to any third party actively tracked catheters for commercial use, within the meaning of the Development Agreement, that are intended to be used with a non-Siemens MRI system.

The Development Agreement contains a cross-licensing arrangement between Siemens and the Company. Under that arrangement, each party granted the other party a non-exclusive license to use certain intellectual property rights owned by the granting party and realized in the research software platform developed under the Original Agreement. Under its license from Siemens, the Company may use the licensed intellectual property rights to develop, manufacture and sell software, provided that during the parties’ exclusivity period and within the exclusivity field, any such software must be solely for use with Siemens MRI systems. Under its license from the Company, Siemens may also use the licensed intellectual property rights to develop, manufacture and sell software, provided that during the parties’ exclusivity period and within the exclusivity field, any such software must be solely for use with the Company’s catheters.

Under the Development Agreement, Siemens designated the Company as Siemens’ Therapy Partner of Choice in the field of MRI-guided catheter-based cardiac electrophysiology using actively tracked catheters. The Development Agreement contemplates that the Company and Siemens may enter into a separate co-marketing agreement pursuant to which parties would cooperate and work together on marketing initiatives.

The term of the Development Agreement will expire four years following the European product release date of the Host Features for MAGNETOM Systems.

The foregoing disclosure includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements often can be identified by words such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would,” or the negative of these words or other words of similar meaning. Forward-looking statements by their nature address matters that, to different degrees, are uncertain and involve risk. Uncertainties and risks may cause the Company’s actual results and the timing of events to differ materially from those expressed in or implied by the Company’s forward-looking statements. Particular uncertainties and risks include, among others: the Company’s ability to successfully complete the development of, and to obtain regulatory clearance or approval for, its ClearTrace system; demand and market acceptance of the Company’s products; availability of third party reimbursement from third party payors for procedures utilizing the Company’s products; the sufficiency of the Company’s cash resources to maintain planned research and development programs and commercialization efforts; future actions of the FDA or any other regulatory body that could impact product development, manufacturing or sale; the Company’s ability to protect and enforce its intellectual property rights; the Company’s dependence on collaboration partners; and the impact of competitive products and pricing. More detailed information on these and additional factors that could affect the Company’s actual results and the timing of events are described in the Company’s quarterly report on Form 10-Q filed on November 13, 2013.

Item 1.02. Termination of a Material Definitive Agreement.

The information set forth under Item 1.01 above regarding the Original Agreement is incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

On February 24, 2014, the Company issued a press release announcing the Development Agreement. A copy of the press release is furnished herewith as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:     February 24, 2014

6